“An efficacy study conducted in Bahrain in accordance with WHO recommendations with the participation of more than 5 thousand people, confirmed the effectiveness of the drug at the level of 94.3% 14 days after receiving the second component.
We analyzed the data obtained in the period from February to the beginning of May this year, ”reads a message published on the RDIF website.
According to the fund, "while 98.6% of all cases of coronavirus recorded two weeks after receiving the second component" Sputnik V "were mild."
The RDIF noted that “vaccination data in Bahrain also confirm the safety of Sputnik V: no serious adverse events associated with vaccination with the Russian drug were identified;
no vaccine-related deaths have been reported;
there are no cases of cerebral venous thrombosis (CVT) after vaccination. "
The Russian Ministry of Health recalled that the effectiveness of the domestic vaccine against coronavirus Sputnik V is 97.6%.
Russian President Vladimir Putin said earlier that the Russian drug has proven its effectiveness and is recognized as the safest.